A comparison of 6-, 12-, and 24-monthly dosing with ivermectin for treatment of onchocerciasis

Bruce M. Greene, Zwannah D. Dukuly, Beatriz Munoz, Albert T. White, Michel Pacque, Hugh R. Taylor

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


This study was designed to examine the optimal dose and interval of administration of ivermectin, the now-accepted drug of choice for onchocerciasis. Two hundred Liberians with Onchocerca volvulusinfection received 100, 150, or 200 ltg/kg ivermectin or placebo and werefollowed for 36 months. The reaction after the second dose of ivermectin was significantly less than after the initial dose, although it was still significant in the 200-ltg/kg group. The skin microfilaria counts in the group treated 6-monthly with 150 ltg/kg was significantly less than in the group treated yearly (12and 24 months after initial therapy). Prevalence of microfilariae in the anterior chamber and punctate corneal opacities decreased progressively in all groups over 3 years. There appears to be a slight advantage, in terms of antiparasitic effect over the first 2 years, of therapy given 6-monthly compared with yearly.

Original languageEnglish (US)
Pages (from-to)376-380
Number of pages5
JournalJournal of Infectious Diseases
Issue number2
StatePublished - Feb 1991

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'A comparison of 6-, 12-, and 24-monthly dosing with ivermectin for treatment of onchocerciasis'. Together they form a unique fingerprint.

Cite this